跳转至内容
Merck
CN

A1862

Sigma-Aldrich

Alpidem

≥98% (HPLC), powder

别名:

6-Chloro-2-(4-chlorophenyl)-N,N-dipropyl-imidazo[1,2-a]pyridine-3-acetamide, 6-Chloro-2-(p-chlorophenyl)-N,N-dipropylimidazo(1,2-a)pyridine-3-acetamide, Ananxyl, SL 80.0342-00

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C21H23Cl2N3O
CAS号:
分子量:
404.33
MDL编号:
UNSPSC代码:
12352200
PubChem化学物质编号:

方案

≥98% (HPLC)

表单

powder

颜色

white to tan

溶解性

DMSO: ≥10 mg/mL

创始人

Sanofi Aventis

储存温度

2-8°C

SMILES字符串

CCCN(CCC)C(=O)Cc1c(nc2ccc(Cl)cn12)-c3ccc(Cl)cc3

InChI

1S/C21H23Cl2N3O/c1-3-11-25(12-4-2)20(27)13-18-21(15-5-7-16(22)8-6-15)24-19-10-9-17(23)14-26(18)19/h5-10,14H,3-4,11-13H2,1-2H3

InChI key

JRTIDHTUMYMPRU-UHFFFAOYSA-N

基因信息

human ... TSPO(706)

生化/生理作用

Alpidem is a potent antagonist of peripheral benzodiazepine receptor (PBR) that is located on the outer mitochondrial membrane and interacts with the mitochondrial permeability transition (MPT) pore. Alpidem is an anxiolytic drug from the imidazopyridine family. Alpidem acts selectively on the α3 receptor subtype and to a lesser extent at the α1 subtype (Kd of 0.33nM and 1.67nM respectively), of the benzodiazepine receptor.
Alpidem is a potent peripheral benzodiazepine receptor (PBR) antagonist.

特点和优势

This compound is a featured product for Neuroscience research. Click here to discover more featured Neuroscience products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.
This compound is featured on the GABAA Receptors page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
This compound was developed by Sanofi Aventis. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

象形图

Exclamation mark

警示用语:

Warning

危险声明

危险分类

Acute Tox. 4 Oral

储存分类代码

11 - Combustible Solids

闪点(°F)

Not applicable

闪点(°C)

Not applicable


历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本?

如果您需要特殊版本,可通过批号或批次号查找具体证书。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

M Anzini et al.
Journal of medicinal chemistry, 39(21), 4275-4284 (1996-10-11)
Alpidem (1), the anxiolytic imidazopyridine, has nanomolar binding affinity for both the central benzodiazepine receptor (CBR) and the peripheral benzodiazepine receptor (PBR). A novel class of PBR ligands related to alpidem has been designed by comparing the interaction models of
[Subfulminant hepatitis caused by alpidem and treated by liver transplantation].
P Ausset et al.
Gastroenterologie clinique et biologique, 19(2), 222-223 (1995-02-01)
Y Gaillard et al.
Journal of chromatography, 622(2), 197-208 (1993-12-22)
A rapid twin-column gas chromatographic (GC) method for simultaneous screening and determination of commonly prescribed benzodiazepines and other new anxiolytics from plasma is described. Identical fused-silica Ultra 2 (5% phenyl methyl silicone) columns were connected to nitrogen-phosphorus and electron-capture detectors.
J F O'Hanlon et al.
Neuropsychobiology, 31(2), 81-88 (1995-01-01)
Effects of benzodiazepine (diazepam, lorazepam) and benzodiazepine-like anxiolytics (alpidem, suriclone) and a 5-HT-3 antagonist (ondansetron) on actual driving performance were measured in three double-blind, placebo-controlled studies. Subjects were healthy volunteers in two and anxious patients in the third. Treatments lasted
A Chodera et al.
Polish journal of pharmacology, 46(5), 479-481 (1994-09-01)
The development of tolerance to the pharmacodynamic effects of azopirone (buspirone) and imidazopyridines (alpidem and zolpidem) was investigated. It was found that tolerance to the anxiolytic effect of buspirone develops only after 42 days of administration (twice daily). Of the

商品

We offer many products related to GABAA receptors for your research needs.

DISCOVER Bioactive Small Molecules for Neuroscience

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门